Dry AMD can affect central vision over time. Geographic atrophy (GA) is an advanced form of #dryAMD. Ocugen’s #OCU410 is an investigational one-time gene therapy in Phase 3 for GA. Notice changes in your vision? Speak with your eye care specialist. #EyeHealth

Ocugen and Roots Pharmaceutical have completed a licensing agreement for #OCU400 in MENA, advancing global commercialization. Terms include up to $4M in upfront and initial development milestones, $255M in potential sales milestones, and 22% royalties on net sales. $OCGN Read more: bit.ly/47OVm06

An important milestone at #AAO2026! During the @aao_ophth Annual Meeting, Raj K. Maturi, MD, presented 12-month safety and efficacy results from our Phase 2 ArMaDa trial evaluating #OCU410 for #geographicatrophy, supporting its continued advancement in Phase 3. #GeneTherapy $OCGN Read more from @ophth_advisor: bit.ly/4e9Qh67

Innovation took center stage at #CGMesa26. Ocugen CEO @drsmusunuri joined investors and industry leaders to discuss the future of #GeneTherapy and the road to commercialization as we advance three Phase 3 programs designed to address multiple disease pathways, not just a single mutation, with the potential to treat major blindness diseases. @alliancerm #InvestorRelations $OCGN

Jolanda Crombach, MSc PharmD, has been appointed General Manager of our newly established European affiliate, headquartered in Amsterdam, to support our three Phase 3 novel modifier #GeneTherapy programs and potential #commercialization. #Biotech $OCGN Read more: bit.ly/4y1ImyI

Ocugen will present its novel modifier #genetherapy platform at upcoming scientific conferences, including EIS 2026, the 26th @EURETINA Congress 2026, and the @aao_ophth Annual Meeting 2026. Read more: bit.ly/3Tww5UQ #EURETINA26 #AAO2026 #Ophthalmology $OCGN

Ocugen CEO @drsmusunuri will participate in @HCWCO: #Biotech on Tap and the Cell & Gene Meeting on the Mesa this October, sharing updates on our gene therapy programs with the investment community. @alliancerm #CGMesa26 #InvestorRelations $OCGN Read: bit.ly/3VC4ana

Hear from CEO @drsmusunuri on how the LARTA Board in the Bahamas is enabling access to #OCU400 for #retinitispigmentosa through an Expanded Access Program with #commercialpricing and its potential to help patients worldwide. @MOHW242 #Genetherapy $OCGN 🔗 bit.ly/4xNFDZR

#OCU400, our #genetherapy for #retinitispigmentosa, received provisional approval and priority designation from the LARTA Board in the Bahamas, a significant step as we advance our mission globally. @MOHW242 $OCGN #CommercialPricing 🔗bit.ly/4xNFDZR

Ocugen CEO @drsmusunuri will join industry leaders at #CGMesa26 for the “Leadership Perspectives: Beyond Breakthrough” panel on October 6 in Phoenix, AZ. Learn more: meetingonthemesa.com @alliancerm #Biotech #GeneTherapy

What is #OCU410, and what does Phase 3 clinical trial mean? OCU410 is an investigational gene therapy with the potential to treat #geographicatrophy secondary to #dAMD. Swipe through to learn about OCU410 and Phase 3. Like, follow, and repost if you found this info helpful!

We participated in the @HCWCO 28th Annual Global Investment Conference, where CEO @drsmusunuri reflected on our progress and shared what’s ahead for #Ocugen as we work to shape the future of vision. Watch the replay: bit.ly/46rSohq $OCGN #GeneTherapy #Biotech

A productive day last week at the @Citi 2026 Biopharma Back to School Conference in NYC. CEO @drsmusunuri shared Ocugen’s progress and the potential of our modifier #genetherapy platform to address major blindness diseases affecting millions. $OCGN

Central vision helps us read, recognize faces, navigate, and see important details. #Geographicatrophy can affect the macula, impacting the central vision we rely on every day. Help spread the word by sharing this information. #EyeHealth

This week, we welcomed @RepBorowski and @RepFriel to Ocugen to meet with CEO @drsmusunuri and our team. We shared our pipeline and work underway, discussed the potential impact of HB 2162, and exchanged perspectives on advancing #biotech innovation in PA. #LifeSciences

Today, CEO @drsmusunuri announced a major advancement for #OCU410 and #geographicatrophy: the first patient dosed in our global Phase 3 trial. We are one step closer to a potential one-time treatment for life and our target of 3 BLAs by 2028. 🔗bit.ly/4qNMBMk $OCGN

We’re pleased to welcome Beth Scott as VP, Head of Clinical Development at #Ocugen. Beth brings 30+ years of ophthalmology experience, including deep expertise in retinal clinical development and trial execution, as we advance #OCU400, #OCU410, and #OCU410ST. #BiotechLeadership